Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL

NCT01880411 is registered in ClinicalTrials.gov with HealthBanks Biotech Co., Ltd. as lead sponsor.

NCT NCT01880411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01880411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL
Lead sponsor
HealthBanks Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
June 30, 2013
Completion date
June 30, 2014
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia